Keywords: bayer/onyx, anti-cancer, drug, looking, good, bay, 43-9006
Bayer/Onyx anti-cancer drug looking good
Article | 28 March 2005
BAY 43-9006, an investigational candidate co-developed by Bayer Pharmaceuticals, a unit of Germany's Bayer Healthcare, and USA-based cancer specialist Onyx ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
